Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Buy” from Brokerages
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned an average recommendation of “Buy” from the fifteen ratings firms that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $38.31.
Several equities analysts have recently weighed in on ESPR shares. Citigroup Inc. raised their price target on Esperion Therapeutics to $77.00 in a report on Tuesday, March 21st. J P Morgan Chase & Co raised their price target on Esperion Therapeutics from $22.00 to $50.00 in a report on Tuesday, March 21st. Needham & Company LLC set a $25.00 price target on Esperion Therapeutics and gave the company a “buy” rating in a report on Saturday, March 18th. Deutsche Bank AG started coverage on Esperion Therapeutics in a report on Friday, June 23rd. They set a “buy” rating and a $48.00 price target for the company. Finally, BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th.
Several large investors have recently added to or reduced their stakes in ESPR. BB Biotech AG boosted its stake in Esperion Therapeutics by 7.6% in the first quarter. BB Biotech AG now owns 1,408,542 shares of the biopharmaceutical company’s stock valued at $49,736,000 after buying an additional 100,000 shares during the period. FMR LLC boosted its stake in Esperion Therapeutics by 70.8% in the first quarter. FMR LLC now owns 1,308,588 shares of the biopharmaceutical company’s stock valued at $46,206,000 after buying an additional 542,579 shares during the period. Boxer Capital LLC acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $45,020,000. Credit Suisse AG boosted its stake in Esperion Therapeutics by 26.4% in the first quarter. Credit Suisse AG now owns 878,824 shares of the biopharmaceutical company’s stock valued at $31,030,000 after buying an additional 183,440 shares during the period. Finally, Pinnacle Associates Ltd. boosted its stake in Esperion Therapeutics by 561.6% in the first quarter. Pinnacle Associates Ltd. now owns 770,618 shares of the biopharmaceutical company’s stock valued at $27,211,000 after buying an additional 654,138 shares during the period. 81.45% of the stock is currently owned by institutional investors.
Esperion Therapeutics (NASDAQ:ESPR) traded up 0.39% during trading on Tuesday, reaching $46.61. 462,880 shares of the company’s stock were exchanged. The stock’s market cap is $1.05 billion. The firm has a 50 day moving average of $36.52 and a 200-day moving average of $28.03. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $49.69.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same quarter in the previous year, the company posted ($0.65) earnings per share. On average, equities research analysts anticipate that Esperion Therapeutics will post ($6.78) earnings per share for the current fiscal year.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.